Therapeutically, the increased levels of replication stress in cancer cells with inactivated Cdh1 may create sensitivity to targeted agents that target the replication checkpoint, such as inhibitors of Wee1, ATR or Chk1. This evidence concerns the gene CDH1 and cancer.